UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000033667 |
|---|---|
| Receipt number | R000038355 |
| Scientific Title | Evaluation trial whether honeybee products vary intestinal environment that intended for healthy individuals |
| Date of disclosure of the study information | 2020/01/31 |
| Last modified on | 2022/05/19 09:31:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Evaluation trial whether honeybee products vary intestinal environment that intended for healthy individuals
Acronym
Evaluation trial whether honeybee products vary intestinal environment that intended for healthy individuals
Scientific Title
Evaluation trial whether honeybee products vary intestinal environment that intended for healthy individuals
Scientific Title:Acronym
Evaluation trial whether honeybee products vary intestinal environment that intended for healthy individuals
Region
| Japan |
Condition
Condition
Adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We will evaluate whether usual intake of "lyophilized powder of enzymatic degradated Royal jelly" and "Brazilian green propolis" for 4 weeks modulate intestinal microbioita and intestinal environment that intended for healthy Japanese men and women who are older than 60 years.
We will evaluate intestinal regulating action throught daybook and safety through physical examinations (interviews, auscultation, percussion, inspection, palpation, etc.) and side effects and changes in clinical laboratory values from the baseline evaluation (vist0, week0) to the last evaluation (visit3, week 4).
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
We will evaluate composition of intestinal microbiota of each fecal sample by genetic engenieering method, and short-chain, water-soluble, and low molecular compounds of fecal samples will be instrumentaly analyzed both quantitatively and qualitatively.
(Measuring before and after 4 week intervention)
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Protease digested royal jelly
Intake:2,400 mg
Ingesion:28day
Interventions/Control_2
Brazilian green propolis containing food
Intake:363 mg
Ingesion:28day
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 60 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Target subjects must satisfy the following selection criteria.
1. Healthy Japanese men and women (only menopause statement) aged more than 60 years, at the time of giving informed consent.
2. A person who had experienced defecation from 2days to 5 days during 7 days just before visiting clinic in the period of observation. (Not nessesary to consecutive days)
3. A person who is not using drugs or medical equipment regardless of seasonal, chronic, or unexpected, and is not undergoing rehabilitation therapy.
4. A person who has freely given consent and has understood the purpose of the clinical study.
5. A person whose BMI is 18.5 - 25.0.
6. A person who can refrain from excessive exercise during the clinical study.
7. A person who can take three meals a day basically and refrain from great intemperance during the clinical study.
8. A person who understands that clinical visits are mandatory during clinical study period.
9. A person who is considered fit for the enrollment in the clinical study.
10. A person who doesn't take drugs and supplements that affect intestinal environment during the clinical study.
Key exclusion criteria
The subjects in conflict with any of the following condition are excluded.
1. A person who took Royal jelly, or Propolis supplement even once within 1month at the time of giving informed consent.
2. A person who took drugs such as antibiotics and dietary supplements that may affect examination outocome.
3. A person who cannot agree with not changing the kind and amount of famous fermented foods such as miso, sake, vinegar, yogurt, cheese, kimch, and natto from past lifestyle.
4. A person who has chornic diarrhea easily.
5. A person who takes commercially available laxatives.
6. A person who smokes even once within 1month at the time of giving informed consent.
7. A person who has a food allergy or asthma.
8. A person who has a disorder to absorption, distribution, metabolism, excretion of trial food, such as digestive tract, liver, kidney, heart and cardiovascular system.
9. A person with a history of cerebrovascular disorder and cranial nerve disorder.
10. A person who is suspected alcohol or drug dependence
11. A person who has taken the blood sampling either 200 mL within 4 weeks or 400ml within 3 months at the time of starting this clinical study.
12. A person who participated in other clinical trial including patch test of cosmetics at present and last 3 months.
13. A person who has an irregular habit because of working at night or working under work-shift form.
14. A person whose housemate are participating or willing to participate this clinical study.
15. A person who cannot follow management matter during clinical study period.
16. A person who has a plan to change own lifestyle dramatically, such as travelling to, or staying developing countries during clinical study period.
17. A person who has a plan to be examined with microscopy during clinical study period.
18. A person who had been judged not appropriate as test subject by questionnaire about lifestyle.
19. A person who had been judged not appropriate by principal investigator.
Target sample size
24
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masayuki Sugimoto |
Organization
Medical corporation Koganeibasi Sakura Clinic
Division name
Not applicable
Zip code
Address
2-11-25 Sakuramachi, Koganei-city, Tokyo, 184-0005, Japan
TEL
042-382-5101
info@kb-clinic.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Kohei Muroi |
Organization
Yamada Bee Company, Inc.
Division name
Institute for Bee Product & Health Science R&D development
Zip code
Address
194 Ichiba, Kagamino-cho, Tomata-gun, Okayama 708-0393 Japan
TEL
0868-54-3825
Homepage URL
km1730@yamada-bee.com
Sponsor or person
Institute
Yamada Bee Company, Inc.
Institute
Department
Personal name
Funding Source
Organization
Yamada Bee Company, Inc.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Research Center for Immunological Analysis. Inc.
Name of secondary funder(s)
none
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 01 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 08 | Month | 07 | Day |
Date of IRB
| 2018 | Year | 08 | Month | 21 | Day |
Anticipated trial start date
| 2018 | Year | 08 | Month | 24 | Day |
Last follow-up date
| 2018 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 08 | Month | 07 | Day |
Last modified on
| 2022 | Year | 05 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038355
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
